Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients

Abstract

Influenza A H1N1/09 vaccine elicited a similar antibody response in HIV-infected individuals and in control subjects, whereas SOT recipients had an overall lower response. A second dose of the vaccine only moderately improved vaccine immunogenicity in HIV-infected patients.

Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies

“…This is most likely due to a high number of patients having detectable antibodies pre-vaccination, reflecting previous use of influenza vaccine in our patient cohort [30,34,35]. After taking into consideration the pre-vaccination titers [28], seroconversion rates increased up to 32-38% for influenza A strains, a rate near of the 40% seroconversion rate which is considered as appropriate for the general population [9,36].…”

Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients

“…Similar results were shown in other studies, as a single shot of pandemic vaccination in successfully HAART-treated HIV-infected adults generated an antibody response within 21 days, with rates comparable to healthy adults. 22,23 In contrast, other work has suggested a lower response in HIV-infected individuals, even in successfully treated patients. [18][19][20] It may be speculated that the apparent discrepancy is mainly attributable to the baseline level of reactivity to influenza virus antigen that is clearly higher in the HIV group.…”

“…21 In contrast, other studies reported a good antibody response in successfully HAART-treated HIV patients. 22,23 However, all these studies addressed the humoral response only, and no information about the ability of pandemic vaccine to elicit a strain-specific and cross-reactive T cell response is available in HIV-infected individuals.…”

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

“…[267,268] These findings of reduced immunogenicity extend to adjuvanted vaccines (AS03 and MF-59) among HIV-positive compared to HIV-negative individuals. [269][270][271] Two systematic reviews conducted on the effectiveness of influenza vaccines among HIV-positive populations showed limited evidence of VE in this population and called for more data from RCT settings. [12,13] However, a recent RCT of TIV among HIV-infected adults in South Africa showed a vaccine efficacy of 76% and high levels of serological conversion.…”